Ranibizumab implants approved by FDA for DME offer a more convenient treatment schedule, reducing injection frequency significantly. The phase 3 Pagoda study showed noninferior visual acuity with ...
--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab ...
In addition to comparable BCVA levels, the researchers concluded that the PDS implant “provides effective, durable, and ...
In this study, 4300 patients received 0.3 or 0.5 mg of ranibizumab every 3 months after the initial series of three monthly injections. After the first 3 injections the mean visual acuity improved ...
Basel, 04 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the ...